This content is restricted.
Brief
"On 13/12/2024, the European Medicines Agency (EMA) issued an update regarding Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024. The CHMP recommended approval for 17 new medicines, including Andembry and Beyonttra, which are intended to treat hereditary angioedema and transthyretin amyloidosis, respectively."
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested